World Conference on Oncology & Cancer Care (WCOCC-2026)

  Synthetic Biomarkers in Cancer: A New Frontier in Precision Oncology and Early Cancer Detection Cancer detection is increasingly moving toward technologies that can identify disease earlier, characterize tumors more precisely, and provide clinically useful information with less invasive testing. Conventional biomarkers such as proteins, nucleic acids, circulating tumor DNA, and other tumor-derived signals have transformed cancer diagnosis and monitoring. However, early-stage tumors can release extremely small quantities of detectable material, making early disease difficult to identify through naturally occurring biomarkers alone. Synthetic biomarkers in cancer represent an emerging approach designed to address this challenge. Instead of relying only on signals naturally released by a tumor, synthetic biomarker systems can be engineered to interact with specific biological features of a tumor and generate a detectable signal that can be measured in an accessible biofluid suc...

  Spatial Metabolomics in Cancer: Mapping Metabolic Landscapes for Precision Oncology Introduction Cancer is not a uniform disease. Even within a single tumor, different regions can contain cancer cells, immune cells, fibroblasts, blood vessels, extracellular matrix, and other components of the tumor microenvironment. These regions can differ substantially in nutrient availability, oxygen levels, metabolic activity, immune signaling, and response to treatment. Traditional metabolomics has provided important information about how cancer changes metabolism. However, conventional approaches often analyze metabolites from a mixed biological sample and therefore may lose information about where specific metabolic changes occur within a tumor . Spatial metabolomics in cancer addresses this challenge by combining metabolomics with spatial information. Instead of simply asking which metabolites are present, spatial metabolomics asks where those metabolites are located and how thei...